Journal issues > Issue 2, March 2021 > Intensified neoadjuvant chemotherapy with SBRT for a borderline resectable pancreatic cancer: A plea for prospective evaluation

Intensified neoadjuvant chemotherapy with SBRT for a borderline resectable pancreatic cancer: A plea for prospective evaluation

By: L. Mans MD, M. Pezzullo MD, M.A. Bali MD, PhD, L. Verset MD, PhD, J. Closset MD, C. Bouchart MD, J-L. van Laethem MD, PhD

SUMMARY

Pancreatic ductal adenocarcinoma (PDAC) is the fourth leading cause of cancer-related death and its 5-year overall survival is poor. Surgery remains the only curative treatment but less than 20% of the patients are resectable at diagnosis. New treatment options for the management of metastatic disease have recently emerged, and with them the question of their use in preoperative strategy. Neoadjuvant sequence may increase the achievement of R0 resection margins in borderline resectable tumours but also the proportion of patients who will receive chemotherapy. We report a case of borderline resectable PDAC treated with duodenopancreatectomy after neoadjuvant treatment consisting of chemotherapy and SBRT.

(BELG J MED ONCOL 2021;15(2):79-82)

To read the full artice you have the following options:

* (only possible for healthcare professionals with RIZIV/INAMI/MATRICULE working in the field of Oncology/Hemato-oncology in Belgium and Luxembourg with prescription authorisation)

Purchase this article for €3.03

** (for healthcare professionals with prescribing authorisation working outside the field of Oncology/Hemato-oncology in Belgium and Luxembourg as well as those without prescribing authorisation working as healthcare professional in Oncology/Hemato-oncology in Belgium and Luxembourg, plus persons without prescription authorisation working outside Belgium and Luxembourg, plus healthcare professionals with prescribing authorisation outside Belgium and Luxembourg plus non-healthcare professionals from outside or inside Belgium or Luxembourg)

Top